Lupus (SLE) trials in Germany

In Germany 39 Also abroad 354

39 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Where
Berlin, Cologne, Freiburg im Breisgau, Herne, Leipzig, Mainz
Age
12 years to 100 years
People
550 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06133972 · EU 2023-505929-14-00
Phase 1Taking people
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Where
Mainz, Munich
Age
18 years to 75 years
People
46 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT07629583 · EU 2025-522904-26-00
Phase 3Taking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Where
Berlin, Buxtehude, Dresden, Erlangen, Mainz, Oberhausen
Age
18 years to 75 years
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07332481 · EU 2025-523871-44-00
Phase 3Taking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Where
Aachen, Dortmund, Hannover, Leipzig, Oldenburg, Tuebingen, Wuppertal
Age
18 years to 75 years
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07355218 · EU 2025-524855-30-00
Phase 3Taking people
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Where
Dresden, Heidelberg, Leipzig, Meerbusch, Munich
Age
18 years to 75 years
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07438496 · EU 2025-523552-31-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Where
Berlin, Cologne, Dresden, Freiburg im Breisgau, Gommern, Greifswald, Herne, Jena, Leipzig, Mainz, Munich, Tuebingen
Age
16 years and over
People
450 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00
No phaseTaking people
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Where
Kiel, Mainz
Age
16 years and over
People
223 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07175285
Phase 1Taking people
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
Where
Bonn, Jena, Mainz, Muenster, Munich
Age
18 years to 65 years
People
48 worldwide
Run by
AstraZeneca
See details and how to joinNCT07201558 · EU 2025-522273-10-00
Phase 2Taking people
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
Where
Bad Doberan, Minden, Munich
Age
18 years to 74 years
People
405 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07409181 · EU 2025-523488-39-00
Phase 3Taking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
Berlin, Dresden, Essen, Freiburg im Breisgau, Hanover, Kiel, Mainz, Marburg, Münster, Regensburg, Tübingen, Wuppertal
Age
5 years to 80 years
People
1,072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
Phase 1Taking people
Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Where
Mainz, Regensburg
Age
18 years to 60 years
People
90 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06975787 · EU 2024-518288-37-00
Phase 3Not yet taking people in Germany
Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Beneﬁted from Continued Treatment.
Where
Berlin, Dresden, Kiel, Mainz, Marburg, Muenster, Regensburg, Tuebingen, Wuppertal
People
340 worldwide
Run by
AstraZeneca AB
See details and how to join2026-526419-13-00 · EU 2026-526419-13-00
Phase 1Taking people
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
Where
Heidelberg
Age
18 years to 70 years
People
24 worldwide
Run by
Cullinan Therapeutics Inc.
See details and how to joinNCT06613360 · EU 2024-518780-36-00
Phase 1Taking people
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Where
Augsburg, Cologne, Hanover, Mainz
Age
18 years to 70 years
People
80 worldwide
Run by
CRISPR Therapeutics
See details and how to joinNCT06925542
Phase 1Taking people
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Where
Cologne, Erlangen, Magdeburg
Age
18 years to 70 years
People
72 worldwide
Run by
AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00
Phase 3Enrolling by invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
Where
Berlin, Cologne, Dresden, Freiburg im Breisgau, Gommern, Herne, Jena, Leipzig, Mainz, Munich, Tuebingen
Age
16 years and over
People
760 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00
Phase 1Not yet taking people in Germany
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Where
Berlin, Erlangen, Magdeburg, Würzburg
Age
18 years and over
People
60 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07873931
Phase 1Not yet taking people in Germany
A study to learn how dapirolizumab pegol transfers to babies from pregnant mothers with active systemic lupus erythematosus
Where
Munich
Age
Up to 64 years
People
10 worldwide
Run by
UCB Biopharma
See details and how to join2025-524595-37-00 · EU 2025-524595-37-00
Phase 3Enrolling by invitation
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
Where
Cologne, Mainz
Age
18 years and over
People
864 worldwide
Run by
Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00
Phase 2Taking people
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Where
Cologne, Düsseldorf, Leipzig, München
Age
18 years to 75 years
People
220 worldwide
Run by
Amgen
See details and how to joinNCT06570798
Phase 2Taking people
A Phase II, Open-Label, Single-Center, Single-Arm Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Blinatumomab for Treatment of Patients with Autoimmune B-Cell driven Diseases including Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) and Granulomatous Polyangiitis (GPA), BlinA-B trial
Where
Leipzig
Age
18 years and over
People
5
Run by
Universitaet Leipzig
See details and how to join2025-523061-22-00 · EU 2025-523061-22-00
Phase 3Taking people
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Where
Bad Abbach, Bad Bramstedt, Mainz, Munich
Age
18 years and over
People
113 worldwide
Run by
AstraZeneca AB
See details and how to join2025-523670-17-00 · EU 2025-523670-17-00
Phase 3Taking people
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Where
Berlin, Freiburg im Breisgau, Sankt Augustin
Age
5 years to 17 years
People
100 worldwide
Run by
AstraZeneca
See details and how to joinNCT05835310 · EU 2022-502289-25-00
Phase 3Taking people
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Where
Bad Abbach, Hamburg, Mainz, München
Age
18 years to 70 years
People
245 worldwide
Run by
AstraZeneca
See details and how to joinNCT07430306
Phase 3Not yet taking people in Germany
A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]
Where
Darmstadt
Age
18 years to 76 years
People
404 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07840287 · EU 2026-525294-39-00